Crinetics Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
The conference highlighted a strong commercial launch for PALSONIFY, robust clinical pipeline progress, and positive payer dynamics. Key milestones include phase 3 trials for carcinoid syndrome and CAH, a positive EU regulatory outlook, and sustained funding into 2030.
-
Significant progress was made with the approval and launch of Palsinify, strong early revenue, and broad prescriber adoption. The pipeline advanced with positive atumelnant data and new clinical programs, supported by $1.4 billion in funding and a clear strategy for long-term growth.
-
Palsonify's launch saw strong early adoption, broad prescriber engagement, and rapid payer coverage, generating over $5 million in first-quarter revenue. Atumelnant's phase II and OLE data show robust, sustained androgen reduction and favorable safety, supporting high confidence in the ongoing phase III Calm-CAH trial.
Fiscal Year 2025
-
2025 marked a pivotal year with the successful U.S. launch of PALSONIFY, strong early uptake, and expanding payer coverage. Robust financials, a $1.4B cash position, and advancing late-stage pipeline position the company for continued growth and innovation.
-
Strong early launch for Palsanafy with rapid patient uptake, positive prescriber and payer feedback, and robust community engagement. Q3 saw increased R&D and SG&A expenses, with a $1.1B cash position supporting operations into 2029. Pipeline progress continues in CAH and oncology.
-
Palsonify received FDA approval as a first-line oral therapy for adults with acromegaly, supported by robust clinical data showing efficacy and safety. The launch includes broad access initiatives, rapid patient support, and a focus on symptom control, with expectations for widespread adoption and payer coverage within six to nine months.
-
Q2 2025 saw strong progress toward PALSONIFY approval and launch, with robust financials and pipeline advancement. Commercial and clinical teams are prepared for U.S. and EU launches, supported by $1.2B in cash and a narrowed 2025 cash use outlook.
-
Key pipeline programs include a TSH receptor antagonist for Graves’ disease, a selective SST3 agonist for ADPKD, and a novel NDC platform targeting SST2-expressing tumors. All programs show strong preclinical data and are advancing toward clinical trials, supported by a robust financial position and a patient-focused strategy.
-
Preparations are underway for a major drug launch in acromegaly, with a PDUFA date set for September 25. The company is advancing a robust pipeline, including atumelnant for CAH and Cushing's, and is well-funded through 2029. Strong payer interest and patient engagement support a positive outlook.
-
Q1 2025 saw increased R&D and SG&A spending as the company prepares for the anticipated paltusotine launch, with strong cash reserves supporting operations into 2029. Regulatory reviews for paltusotine and atumelnant are on track, and global expansion is underway.
-
Significant 2024 progress includes Paltusotine's NDA acceptance and strong Atumelnant Phase 2 data, with multiple new INDs planned. The pipeline leverages a robust discovery platform, targeting unmet needs in endocrinology and oncology, with several programs advancing to pivotal trials.
-
Multiple late-stage programs are advancing, including paltusotine for acromegaly and carcinoid syndrome and atumelnant for CAH and Cushing's disease. The pipeline features innovative platforms and a focus on expanding patient care and market reach.
-
The organization is advancing a robust pipeline in endocrine and adjacent diseases, highlighted by the upcoming launch of paltusotine for acromegaly and strong phase II results for atumelnant in CAH. Financial strength and a focus on patient-centric innovation support multiple late-stage trials and new INDs in 2024 and 2025.
-
Phase II results for atumelnant in adults with classic CAH showed rapid, dose-dependent, and sustained reductions in key hormonal biomarkers, with significant clinical improvements and a favorable safety profile. Plans are underway to initiate phase III trials in adults and pediatric patients using 80 and 120 mg doses.
Fiscal Year 2024
-
Achieved all 2024 objectives, advancing late-stage clinical programs and preparing for the commercial launch of paltusotine, with strong financials supporting operations into 2029. R&D and SG&A expenses rose as pipeline and commercial activities expanded, and regulatory filings are on track for 2025.
-
Key programs are advancing toward IND submissions in 2025, with promising preclinical and interim clinical data in endocrine and oncology indications. Commercial infrastructure is being built for upcoming product launches, and management projects strong long-term growth and value creation.
-
The event highlighted a robust pipeline targeting endocrine and related diseases, with several candidates advancing to clinical trials. Key programs include oral therapies for acromegaly and carcinoid syndrome, and innovative approaches for CAH and Cushing’s. Long-term vision centers on sustained growth and leadership in endocrinology.
-
Multiple endocrinology programs are advancing, with key data updates for atumelnant in early 2025 and a focus on expanding clinical indications. New therapies for hyperparathyroidism and neuroendocrine tumors are entering first-in-human studies, with additional assets in obesity and TSH progressing.
-
Submitted NDA for paltusotine in acromegaly with FDA review expected; strong cash position of $1.4B post-offering funds operations into 2029. Multiple late-stage trials and new pipeline candidates, including a novel NDC platform, are advancing, with increased R&D spend anticipated.
-
The company is advancing a robust endocrinology pipeline, highlighted by paltusotine for acromegaly and atumelnant for Cushing's and CAH, with NDA submission planned this fall. Commercial strategy emphasizes deep community engagement, patient education, and expanding access to innovative oral therapies.
-
The conference highlighted progress on paltusotine, with strong phase III results in acromegaly and positive phase II data in carcinoid syndrome, supporting an NDA submission by year-end. Atumelnant showed promising phase II results in CAH, with pivotal studies planned for 2025, and early-stage programs are advancing toward the clinic.
-
Strong Q2 progress included positive phase II data for atumelnant, robust phase III results for paltusotine in acromegaly, and a solid cash position of $863 million. NDA filing for paltusotine is on track for 2024, with multiple pipeline advances and a key partnership with Eli Lilly.
-
Atumelnant, an oral ACTH antagonist, showed rapid, profound, and sustained reductions in key biomarkers for both CAH and Cushing's disease in phase II studies, with normalization of hormone levels and symptom improvements. The drug was well-tolerated, and further studies are planned to support phase III development.